NewcelX Ltd.
corporate_fare Company Profile
NewcelX Ltd. (NASDAQ:NCEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for NCEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for NCEL spans 6-K, F-3/A, F-3, SCHEDULE 13D.
Recent high-impact activity:
- NewcelX Raises $1.55M at 20% Premium to Market, Led by Healthcare Investors
- NewcelX Offloads Mazindol Portfolio for $500K Upfront, Up to $55M in Milestones
- NewcelX Flags Substantial Doubt About Going Concern as Cash Drops to $710K
- NewcelX Locks In $1.4M Private Placement at $4.033/Share, a 24% Premium to Market
- NewcelX Prices $1.4M Private Placement at 20% Premium, Bolstering Diabetes Program
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 10,468 shares in NCEL as of the October 30, 2026 settlement, a 6.9% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 53.7% of NCEL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for NCEL, detected from its recent SEC filings · based on capital-structure filings through 2026-06-30.
Shareholder Proposals Approved · Authorization of New Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NCEL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.